News

PipelineReview.com3h
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue
OSLO, Norway I June 30, 2025 I BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they ...
PipelineReview.com3h
XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations
CAMBRIDGE, MA, USA I June 30, 2025 I XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance ...
PipelineReview.com3h
ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility
LAUSANNE, Switzerland and COPENHAGEN, Denmark I July 01, 2025 I ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine ...
PipelineReview.com3h
HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach
TAIPEI, Taiwan and SHANGHAI, China and SAN FRANCISCO, CA, USA I July 1, 2025 I HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company ...
PipelineReview.com3h
UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss
Rincell-1 addresses a multi $Bn global market opportunity where no disease modifying treatments currently exist ...
PipelineReview.com3h
Camurus’ Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
LUND, Sweden I July 1, 2025 I Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous ...
PipelineReview.com6h
Sensorion Announces Preliminary Positive Data from the First Cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial
MONTPELLIER, France I July 01, 2025 I Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of ...
PipelineReview.com6h
Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program
SAN DIEGO, CA, USA I June 30, 2025 I Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...
PipelineReview.com6h
Iksuda Therapeutics Receives FDA IND Clearance for IKS014
FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore. Preliminary data from an ongoing dose-escalation study of IKS014 has shown ...
PipelineReview.com22h
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
CAMBRIDGE, MA, USA I June 30, 2025 I Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 ...
PipelineReview.com23h
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease
In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) ...
PipelineReview.com22h
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
TYRA-300 is a potential first-in-class, investigational, oral, FGFR3-selective inhibitor designed to minimize the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic ...